Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.

Klingler TM, Martens UM, Riera-Knorrenschild J, Wessendorf S, Ettrich T, Kanzler S, Lugani S, Rohleder E, Stahler A, Hasenburg AA, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Geissler M, Modest DP, Werner J

Open source

DOI: 10.1016/j.ejca.2026.117045
Published: 2026 Sep 11
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.117045,
  title = {Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.},
  author = {Klingler TM and Martens UM and Riera-Knorrenschild J and Wessendorf S and Ettrich T and Kanzler S and Lugani S and Rohleder E and Stahler A and Hasenburg AA and Held S and Buechner-Steudel P and Atzpodien J and Heinemann V and Geissler M and Modest DP and Werner J},
  year = {2026},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2026.117045},
  url = {https://doi.org/10.1016/j.ejca.2026.117045}
}

RIS

TY  - JOUR
TI  - Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.
AU  - Klingler TM
AU  - Martens UM
AU  - Riera-Knorrenschild J
AU  - Wessendorf S
AU  - Ettrich T
AU  - Kanzler S
AU  - Lugani S
AU  - Rohleder E
AU  - Stahler A
AU  - Hasenburg AA
AU  - Held S
AU  - Buechner-Steudel P
AU  - Atzpodien J
AU  - Heinemann V
AU  - Geissler M
AU  - Modest DP
AU  - Werner J
PY  - 2026
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2026.117045
UR  - https://doi.org/10.1016/j.ejca.2026.117045
ER  -

APA

TM, K., UM, M., J, R., S, W., T, E., S, K., S, L., E, R., A, S., AA, H., S, H., P, B., J, A., V, H., M, G., DP, M., & J, W. (2026). Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2026.117045

Source records

pubmed · retrieved 2026-09-25T07:13:53.102Z

Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records

Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.